Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers near a buy zone.

The FDA’s Office of Prescription Drug Promotion sent Travere Therapeutics a letter over its advertising for Filspari, a drug that’s approved to slow kidney function decline in people with primary IgA ...

The "Focal Segmental Glomerulosclerosis - Market Insight, Epidemiology, Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The report provides an in-depth assessment of FSGS ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

Janus Henderson's Global Life Sciences portfolio returned 12.10% in Q2 2026, outperforming its benchmark. Read the full ...

On August 6, Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results showing royalty revenue up 32% year ...

Excited to Join Travere Therapeutics as Director, Scientific Engagement and Professional Societies / AbbVie Oncology, Asud ...

Mineralys is upgraded to Buy, with lorundrostat poised for FDA approval in December and a strong commercial launch ...

Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you ...